Quick Listen: Scrip’s Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: a history of Alzheimer’s drug development; BioNTech looks beyond COVID-19 vaccines; gene therapy setbacks for bluebird; new promise for Roche’s Polivy in B-cell lymphoma; and rising US momentum for US drug price negotiations.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 13 August 2021, including: a history of Alzheimer’s drug development; BioNTech SE looks beyond COVID-19 vaccines; gene therapy setbacks for bluebird bio; new promise for Roche Holding AG’s Polivy in B-cell lymphoma; and US momentum for US drug price negotiation rises.
This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode: